New Drug Approvals Archive - December 2011
Anturol (oxybutynin) Gel
Date of Approval: December 7, 2011
Company: Antares Pharma, Inc.
Treatment for: Overactive Bladder
Anturol (oxybutynin) is an anticholinergic transdermal gel formulation indicated for the management of overactive bladder.
Read more: Anturol (oxybutynin) FDA Approval History
New Formulation Approved: December 9, 2011
Read more: Opana (oxymorphone) FDA Approval History
Edarbyclor (azilsartan medoxomil and chlorthalidone) Tablets
Date of Approval: December 20, 2011
Company: Takeda Pharmaceutical Company Limited
Treatment for: Hypertension
Edarbyclor (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a diuretic, indicated for the treatment of hypertension.
Patient Population Altered: December 21, 2011
Read more: Isentress (raltegravir) FDA Approval History